GLP-1 gip vs tirzepatide
You are deciding between two options.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
These are not two things. Tirzepatide is the GIP/GLP-1 medication — the phrase describes what tirzepatide is, so the comparison collapses as soon as you look at the label.
What GIP actually is
Glucose-dependent insulinotropic polypeptide — a separate incretin hormone, not part of the proglucagon family at all.
- FDA-approved medication
- Yes
- Approved for
- No GIP-only medication is marketed. GIP is targeted alongside GLP-1 by tirzepatide.
- Example
- Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist
- Difference that matters
- Not an alternative to GLP-1 but a second target hit at the same time. The Zepbound label describes tirzepatide as "a GIP receptor and GLP-1 receptor agonist".
This page describes what each thing is and what it is approved for. It does not compare how well they work, because that is a question for a prescriber with your history in front of them.
In the label's own words, tirzepatide "is a GIP receptor and GLP-1 receptor agonist". It is sold as Zepbound for weight management and as Mounjaro for type 2 diabetes; both are the same molecule with different indications and different labelling.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
| Mounjaro Eli Lilly | Tirzepatide | Type 2 diabetes | Weekly | 2.5 mg | 15 mg | 6 |
The comparison people usually mean is dual-target versus GLP-1 alone — tirzepatide against semaglutide. That is a real distinction in mechanism, and the products are laid out side by side on the semaglutide versus tirzepatide page.
Zepbound titration schedule
Tirzepatide · once weekly · subcutaneous injection · as published in the prescribing information
| Step | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose — not intended for weight loss effect |
| Weeks 5–8 | 5 mg | — |
| Weeks 9–12 | 7.5 mg | — |
| Weeks 13–16 | 10 mg | — |
| Weeks 17–20 | 12.5 mg | — |
| Week 21+ | 15 mg | Maximum dose |
This is the labelled default. Holding at a step longer than shown is common practice and is a decision for your prescriber. Transcribed from the Zepbound prescribing information (label revised 6 May 2026); checked against that label on 7 August 2026.
Common questions
- So Zepbound is a GIP drug?
- Zepbound is a brand of tirzepatide, which targets both GIP and GLP-1 receptors. Calling it a GIP drug is half the description.
- Are there other dual agonists?
- Tirzepatide is the dual GIP/GLP-1 agonist approved in the US. Other multi-target molecules are in development; this site covers approved products with published labels.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: glp-1 gip vs tirzepatide